Please upgrade your browser.
Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug’s overall tolerability without affecting its efficacy, say Japanese researchers.
The Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute has opened a novel Phase III, vaccine-based clinical trial aimed at providing kidney cancer patients long-term control of their disease.
To compare outcomes of metastatic renal cell carcinoma (mRCC) patients treated with everolimus, temsirolimus, and sorafenib following initial treatment with a tyrosine kinase inhibitor (TKI) in community and academic practices throughout the US.
Sunitinib demonstrated encouraging activity and manageable toxicities in patients with metastatic renal cell carcinoma and renal insufficiency, according to study results.
According to The Heritage Foundation, Obamacare disrupts nearly all areas of health care. Governed by an independent Board of Trustees, The Heritage Foundation is an independent, tax-exempt institution.
New patient information is now available on Cancer.Net about the coverage of costs for research study participation under the Affordable Care Act (ACA), which now requires health insurance companies to cover routine costs associated with approved clinical trials.
Despite large gains in health over the past few decades, the distribution of health risks worldwide remains extremely and unacceptably uneven.
Choroidal metastases generally appear as a solitary, yellow- or orange-colored mass in the macula or perimacular region of the eye. In an analysis of 520 eyes with uveal metastasis, the tumor appeared as a solitary mass (71%) with mean basal dimension of 9 mm and mean thickness of 3 mm.1 In that analysis, associated findings included subretinal fluid (73%) and retinal pigment epithelial alterations (57%). Hemorrhage is an unusual finding with choroidal metastatic disease. Single case reports have highlighted this rare association.
The SWITCH trial makes it official: it makes no difference whether patients with metastatic renal cell carcinoma (mRCC) first start on sorafenib and then switch to sunitinib upon progression or vice versa.
Prognostic Tools that Help Make Sense of Localized RCC Heterogeneity, Guide the Decision-Making Process
One of the greatest challenges clinicians face in treating patients with small renal masses is to make sense of tumor heterogeneity and determine how best to treat these individuals.
|Powered by NeonCRM|